DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 01:10:20 08/06/2024 am IST | ||
| 36.78 EUR | +1.86% |
|
| Current month | +1.46% | ||
| 1 month | -5.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 36.78 | +1.86% |
| 06/24/06 | 36.11 | -0.71% |
| 05/24/05 | 36.37 | -1.17% |
| 04/24/04 | 36.8 | -0.16% |
| 03/24/03 | 36.86 | +1.68% |
Delayed Quote Deutsche Boerse AG
Last update June 08, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE9PM0 |
| ISIN | DE000PE9PM03 |
| Date issued | 22/02/2023 |
| Maturity | 20/12/2024 (196 Days) |
| Parity | 1 : 1 |
| Emission price | 40.82 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 42.88 € |
|---|---|
| Lowest since issue | 35.53 € |
| Spread | 0.07 € |
| Spread % | 0.19% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- Certificat
